Asgard Therapeutics today announce a €30 million Series A financing. The round was co-led by RV Invest and Johnson & Johnson Innovation – JJDC, Inc., with participation from existing investors Novo Holdings, Boehringer Ingelheim Venture Fund and Industrifonden.
Read moreAsgard Therapeutics announces today the presentation of a poster showcasing positive in vivo data. These data will be presented at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will take place in San Diego, California November 1-5, 2023.
Read moreAsgard Therapeutics proudly announces the addition of Dr. Ulrich Lauer, MD, and Dr. Aurélien Marabelle, MD PhD to its Scientific Advisory Board (SAB) during its second SAB annual meeting. The addition of these two leading experts in clinical immuno-oncology is a timely complement to Asgard's SAB, given the recent milestone of achieving preclinical proof-of-concept to AT-108 lead program.
Read moreAsgard's Therapeutics CEO Cristiana Pires has been honored with the prestigious 2022 annual Rosalind Franklin Society (RFS), in partnership with Mary Ann Libert, Inc., publisher, Award in Science for her publication in Cellular Reprogramming journal, co-authored with Filipe Pereira, recognizing exceptional contributions of women and underrepresented minority scientists, physicians, and engineers.
Read moreAsgard Therapeutics is proud to announce the publication in Science Immunology demonstrating reprogramming of over 60 mouse and human tumors cells across a broad spectrum of tumor types into functional antigen-presenting cells.
Read moreOur CEO, Cristiana Pires delivers an engaging interview, delving into the entrepreneurial journey of herself and the co-founders of Asgard Therapeutics, Fábio Fiúza Rosa and Filipe Pereira. This insightful interview recognizes their prestigious award of the Årets Nybyggare (Settler of the Year) in 2022 in the category of Årets Nystart in the South region of Sweden.
Read moreAsgard Therapeutics, led by Co-founder and CEO Cristiana Pires, has been awarded with European Innovation Council WomenTechEU grant among 467 women-led companies that applied. The EU grant empowers women-led deep-tech start-ups, fostering their growth as future leaders in the deep-tech industry.
Read moreAsgard Therapeutics, a Swedish company and project coordinator, announces today, together with the REPRINT project partners, InSphero (CH), Lund University (SE) and Antineo (FR), the achievement of proof-of-principle for using dendritic cell reprogramming to kick start in-vivo anti-tumor immunity.
Read more